Pseudoindoxyl vs 7-Hydroxymitragynine

What is mitragynine pseudoindoxyl?

Mitragynine pseudoindoxyl is a structural rearrangement of the indole ring system of mitragynine, first characterised as part of the medicinal-chemistry programme that explored kratom alkaloid scaffolds for biased opioid agonism (Váradi 2016). In rodent models, the pseudoindoxyl produced morphine-like analgesia with markedly less respiratory depression, less constipation, and reduced tolerance and dependence — a profile attributed to its combination of mu-agonism, delta-antagonism, and the absence of β-arrestin-2 recruitment.

This compound is a preclinical research scaffold, not a kratom product. It does not occur in kratom leaf at pharmacologically meaningful concentrations, and there is no published human clinical data on it.

Why the research interest

The medicinal-chemistry interest in pseudoindoxyls and related mitragynine-derived scaffolds is driven by the possibility of biased mu-opioid agonism — analgesic efficacy without the β-arrestin-2 signalling that has been linked (controversially) to respiratory depression and tolerance (Váradi 2016; Kruegel 2016). Subsequent work has tempered some of those claims; the biased-agonism hypothesis as a clean explanation for opioid safety is contested in the broader literature. Pseudoindoxyl remains a tool compound and a starting point for analogue synthesis, not a validated clinical candidate.

Bottom line for consumers

Mitragynine pseudoindoxyl is not in commercial kratom or 7-OH products at meaningful concentrations. Any product marketed as containing it is either mislabelled, contaminated, or selling something else under that name — none of those scenarios are safe to consume. If you are looking for actual consumer products in this category, the relevant content lives at our brand reviews and product guide; this page is here to clarify a research term, not to point you at a buy decision.